Live on stage — Cell & Gene Leaders Live speakers and moderators

Director of Science and Innovation at Populate, with experience spanning academia, the NHS and the commercial sector.

Chief Executive Officer and Executive Board Member at AviadoBio. Previously Senior Vice President and Chief Business Officer of Novartis Gene Therapies, where she led worldwide commercialisation across its gene therapy portfolio.

A biotechnology engineer specialising in cell and gene therapy CMC, focused on creating scalable, affordable manufacturing solutions for allogeneic cell therapies.

A biotech leader with more than 25 years of experience across academia, technology transfer, university spin-outs and the biopharmaceutical industry.

An advanced-therapies operations leader responsible for CGT Catapult’s Manufacturing Innovation team and GMP facilities, with more than two decades of experience spanning development, tech transfer and scale-up.

A stem-cell scientist and ATMP consultant with more than two decades of experience helping pluripotent stem-cell therapies move from early research towards scalable, regulatory-ready manufacture.

A leading voice for UK life sciences, connecting government, industry and investors to strengthen the country’s health-innovation ecosystem.

An experienced cell-and-gene therapy executive leading Kiji Therapeutics and the development of next-generation immune medicines.

Leads Cellular Origins, bringing advanced automation to cell-therapy manufacturing so promising treatments can be produced reliably at commercial scale.

Meet Alexander Seyf of Autolomous at Cell & Gene Leaders Live.

A founding member of Act for Hope, the foundation bringing the cell and gene therapy community together to speed therapies to patients.

Leads Circio’s work on circular RNA, building a platform designed to deliver durable, next-generation genetic medicines.

Founder of Chromatin Bioscience, which designs cell-type-selective synthetic promoters. Previously built Synpromics into a leading gene control company, acquired by AskBio in 2019.

Leads Rocket Pharmaceuticals, developing gene therapies for rare and devastating diseases.

Founded Aspect Biosystems, which bioprints tissue therapeutics designed to replace or repair tissue in the body.

Meet Dr. Hans Schambye MD, PhD of BOOST Pharma at Cell & Gene Leaders Live.

Meet Jon Ellis of Trenchant BioSystems at Cell & Gene Leaders Live.

CEO and co-founder of Genomics, translating insights from human genetics into better healthcare and drug discovery.

Meet Mike Klein of Genomenon at Cell & Gene Leaders Live.

Meet Dr. Marcos Burger Ramos PhD of Anomer Bio at Cell & Gene Leaders Live.

Meet Dr. Ali Pashazadeh MBBS, MRCS, MBA of Tree Hill Partners at Cell & Gene Leaders Live.

A physician, biotech operator and investor helping advanced-therapy companies turn ambitious science into scalable, patient-ready businesses.

A translational scientist and company builder advancing viral-vector manufacturing and the clinical delivery of cell and gene therapies.

Meet Dr. Stuart Lowe PhD of TTP PLC at Cell & Gene Leaders Live.

Meet Dr. Stuart Curbishley PhD of adthera bio at Cell & Gene Leaders Live.

Managing Director of Bramble Bio, a cell-therapy CDMO. More than 20 years of life-sciences leadership spanning commercialisation and market expansion at Thermo Fisher Scientific, Merck and Becton Dickinson, with a PhD in epigenetics from the Roslin Institute / University of Edinburgh and an MBA from Warwick.

CEO of QVance, a quality-control analytics provider specialising in ATMPs, and CSO of NextCell Pharma, a clinical-stage mesenchymal stromal cell therapy company. 25 years in advanced therapies across the British, German, Finnish and Swedish ecosystems, and European VP Elect of the International Society for Cell & Gene Therapy.

CSO, CQO and Management Board member at ArThec, where he leads scientific and strategic development of the PEARL tissue-engineering platform for cartilage regeneration. More than 20 years across research, GMP manufacturing and clinical development of biologics and advanced therapy medicinal products.

Co-founder and CEO of Korecyte Bio, developing next-generation CAR-based cellular immunotherapies for solid tumours. More than 15 years in life-sciences management, R&D and business development, with a PhD in molecular cell biology.

Senior Director at Resolution Therapeutics, working on macrophage cell-therapy development and translational research. A PhD immunologist with more than a decade of experience taking cell therapies from research towards the clinic.

Co-founder, CEO and Chief Scientist of Lir Therapeutics, an AI viral-vector company engineering AAV capsids for dose reduction, tissue targeting and immune evasion. A former Harvard Medical School postdoctoral fellow with more than a decade of AAV engineering experience and multiple patents in the field.

Chairman, CEO and co-founder of Ocugen, developing modifier gene therapies for blindness. A biotech operator with more than 30 years of experience, including nearly 15 years at Pfizer where he led global operations for Prevnar 13, and founding Nuron Biotech.

CEO of Arbor Biotechnologies, a gene-editing company developing genetic medicines. A cell-and-gene therapy leader with more than 20 years of experience, previously COO and Head of Strategy at Sigilon Therapeutics and COO of Pfizer’s UK-based Neusentis unit.

Chief Executive of the BIA, the trade association for the UK’s innovative life sciences and biotech industry. Previously the founding CEO of Medicines Discovery Catapult, with more than 30 years of UK and international life-sciences experience.

Managing Director of Bayer’s Gene & Cell Therapies Incubator in Berlin, supporting European cell-and-gene therapy start-ups on the path from science to the clinic.

CEO of ImmunoKey, a Manchester-area biotech developing a platform to unlock CAR T-cell therapy for solid cancers. Holds a DPhil in oncolytic virotherapy from the University of Oxford.

Chief Executive Officer and Executive Director of Ori Biotech, which builds manufacturing systems for cell and gene therapies. He has spent more than 20 years building consulting, pharma and technology companies, including Indivior, which listed on the London Stock Exchange in a £2.5 billion exit in 2014.